InvestorsHub Logo
Followers 2
Posts 104
Boards Moderated 0
Alias Born 10/31/2013

Re: None

Friday, 06/07/2024 9:26:28 AM

Friday, June 07, 2024 9:26:28 AM

Post# of 392
RZ402 would compete with Regeneron's Eylea, originally approved in 2011 for treating wet age-related macular degeneration. Developed with Bayer, Eylea has been highly successful, with its original and recently approved higher-dose versions earning $5.89 billion in net sales in 2023.
Valuation of products competition-
If sales of RZ402 equal eyelea sales that’s 147.5/share valuation…. Crazy for a small cap
Handok Inc keeps buying shares the company as well as their officers.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RZLT News